IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.392
AS - Asia 3.733
EU - Europa 2.073
SA - Sud America 817
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 9
Totale 13.084
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.318
SG - Singapore 2.074
UA - Ucraina 835
BR - Brasile 643
CN - Cina 639
VN - Vietnam 319
FI - Finlandia 317
HK - Hong Kong 316
DE - Germania 315
RU - Federazione Russa 167
FR - Francia 127
IE - Irlanda 118
AR - Argentina 88
KR - Corea 86
SE - Svezia 60
TR - Turchia 55
IT - Italia 54
IN - India 45
BD - Bangladesh 39
GB - Regno Unito 37
CA - Canada 30
ID - Indonesia 25
MX - Messico 23
CO - Colombia 19
IQ - Iraq 19
PK - Pakistan 19
EC - Ecuador 18
ZA - Sudafrica 18
CL - Cile 13
UZ - Uzbekistan 13
MA - Marocco 12
AT - Austria 11
PY - Paraguay 10
EU - Europa 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
SA - Arabia Saudita 8
VE - Venezuela 8
JP - Giappone 7
PH - Filippine 7
UY - Uruguay 7
EG - Egitto 6
IL - Israele 6
MY - Malesia 6
DO - Repubblica Dominicana 5
PE - Perù 5
PL - Polonia 5
TN - Tunisia 5
AZ - Azerbaigian 4
BO - Bolivia 4
JO - Giordania 4
KZ - Kazakistan 4
NL - Olanda 4
OM - Oman 4
BG - Bulgaria 3
CR - Costa Rica 3
ES - Italia 3
KG - Kirghizistan 3
NP - Nepal 3
TH - Thailandia 3
AL - Albania 2
AM - Armenia 2
BE - Belgio 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
GY - Guiana 2
JM - Giamaica 2
LB - Libano 2
LT - Lituania 2
NI - Nicaragua 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
ZW - Zimbabwe 2
BB - Barbados 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DJ - Gibuti 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MK - Macedonia 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SV - El Salvador 1
TG - Togo 1
TJ - Tagikistan 1
VC - Saint Vincent e Grenadine 1
Totale 13.084
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 634
Singapore 580
Ashburn 517
Woodbridge 438
Wilmington 370
Seattle 342
Cambridge 329
Houston 317
Hong Kong 312
Chandler 306
Beijing 286
Dearborn 284
Boardman 140
Princeton 134
Ho Chi Minh City 125
Lauterbourg 117
Dublin 116
Ann Arbor 115
San Jose 89
Seoul 85
San Diego 79
Hefei 71
São Paulo 70
Los Angeles 67
Buffalo 56
Hanoi 56
Izmir 41
Helsinki 40
Dallas 39
The Dalles 39
Norwalk 32
Ogden 30
Santa Clara 29
Redondo Beach 26
Udine 26
New York 23
Kunming 22
Da Nang 17
Rio de Janeiro 17
Porto Alegre 15
Curitiba 14
Belo Horizonte 13
Haiphong 12
Nanjing 12
Brasília 11
Des Moines 10
Guangzhou 10
Mumbai 10
Ottawa 10
Tashkent 10
Hải Dương 9
Lahore 9
Nanchang 9
Thái Bình 9
Johannesburg 8
Nuremberg 8
Santo André 8
Turku 8
Campinas 7
Chennai 7
Guayaquil 7
Jinan 7
Montreal 7
Baghdad 6
Brooklyn 6
Chengdu 6
Dhaka 6
Grafing 6
Medellín 6
Nairobi 6
Ninh Bình 6
Orem 6
Pelotas 6
Quito 6
Tokyo 6
Bauru 5
Biên Hòa 5
Bogotá 5
Buenos Aires 5
Cape Town 5
Chicago 5
Indaiatuba 5
João Pessoa 5
Juiz de Fora 5
Manchester 5
Mexico City 5
Montes Claros 5
Montevideo 5
Munich 5
Ribeirão das Neves 5
Santiago 5
São João de Meriti 5
Thái Nguyên 5
Uberlândia 5
Vienna 5
Warsaw 5
Amman 4
Atlanta 4
Baku 4
Totale 7.769
Salva come PNG Salva come JPEG
Nome #
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 280
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 217
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 176
Taxane-induced nail changes: incidence, clinical presentation and outcome 160
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 148
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 143
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 140
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 139
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 139
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 137
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 135
Chemotherapy: which drug and when? 134
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 133
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 133
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 132
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 130
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 130
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 130
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 130
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 130
Bevacizumab plus fluorouracil: the value of being part of a developing story 128
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 127
Determinants of sensitivity and resistance to fluoropyrimidines 126
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 123
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 123
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 122
Current controversies in the adjuvant therapy of colon cancer 120
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 119
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 118
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 118
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 116
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 116
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 116
How uniform are postgraduate training programs in medical oncology in the European Union? 115
Optimal treatment of metastatic colorectal cancer 115
Current strategies to reduce cisplatin toxicity 114
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 114
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 114
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 113
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 112
Fatigue: a main component of anemia symptomatology 112
Urgent need for a new staging system in advanced colorectal cancer 112
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 111
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 111
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 111
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 111
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 110
The potential role of Tomudex in the treatment of advanced colorectal cancer 109
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 109
Role of oxaliplatin in the treatment of colorectal neoplasms 108
Highlights from the 2008 Gastrointestinal Cancers Symposium 108
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 107
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 107
Irinotecan in combination with new agents 106
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 106
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 105
The medical treatment of advanced colorectal 104
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 104
Current issues in adjuvant treatment of stage II colon cancer 104
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 104
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 103
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 103
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 103
Tamoxifen-induced total alopecia 103
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 103
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 101
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 100
Adjuvant treatment of colorectal cancer in the elderly 95
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 95
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 94
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 94
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 92
New directions in the treatment of colorectal cancer: a look to the future 92
Biochemical determinants of antineoplastic activity of fluoropyrimidines 92
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 91
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 91
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 90
Clinical aspects of drug resistance 90
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 90
Improved therapeutic index of cisplatin with procaine HCl 87
THE ROLE OF METHOTREXATE IN THE TREATMENT OF GESTIONAL TROPHOBLASTIC NEOPLASM 86
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 85
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 84
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 82
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 82
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 79
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 78
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 78
The clinical management of early and advanced colorectal cancer 76
Drug resistant cells as targets for new therapies 76
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 76
The handling of metastatic colorectal cancer 76
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 74
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 74
LE ANEMIE 73
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 72
Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay 71
Sequence dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for these interactions 70
Randomized comparison of. weekly bolus five-fluorouracil with or without leucovorin in metastatic colorectal carcinoma 70
Mechanisms of action of 5-8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells in vitro 70
Totale 10.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.648
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.648
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021219 0 0 0 0 0 0 0 0 0 0 173 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/20252.497 38 154 207 71 31 63 89 83 180 297 507 777
2025/20263.197 210 518 340 503 459 255 293 116 168 294 41 0
Totale 13.101